Plasma-derived human butyrylcholinesterase - Baxter Healthcare Corporation/DynPort Vaccine Company LLC

Drug Profile

Plasma-derived human butyrylcholinesterase - Baxter Healthcare Corporation/DynPort Vaccine Company LLC

Latest Information Update: 08 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation; DynPort Vaccine Company LLC
  • Developer Baxter Healthcare Corporation; DynPort Vaccine Company
  • Class Antidotes; Cholinesterases
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Poisoning

Most Recent Events

  • 07 Apr 2008 Preclinical trials in Poisoning in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top